The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer
Abstract
Purpose: The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease. Patients and Methods: A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample external validation set. In parallel, expression signatures that define the status of oncogenic signaling pathways were evaluated in 119 primary ovarian cancers and 12 ovarian cancer cell lines. In an effort to increase chemotherapy sensitivity, pathways shown to be activated in platinum-resistant cancers were subject to targeted therapy in ovarian cancer cell lines. Results: Gene expression profiles identified patients with ovarian cancer likely to be resistant to primary platinum-based chemotherapy with greater than 80% accuracy. In patients with platinum-resistant disease, we identified expression signatures consistent with activation of Src and Rb/E2F pathways, components of which were successfully targeted to increase response in ovarian cancer cell lines. Conclusion: We have defined a strategy for treatment of patients with advanced-stage ovarian cancer that uses therapeutic stratification based on predictions of response to chemotherapy, coupled with prediction of oncogenic pathway deregulation, as a method to direct the use of targeted agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Self-citationWelsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., & Hampton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1176 · Cited by 654
Schummer, M., Ng, W. V., Bumgarner, R. E., Nelson, P. S., Schummer, B., Bednarski, D. W., Hassell, L., Baldwin, R. L., Karlan, B. Y., & Hood, L. (1999) · Gene · doi:10.1016/s0378-1119(99)00342-x · Cited by 402
Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.520 · Cited by 381
Gene Expression Patterns in Ovarian Carcinomas
Schaner, M. E., Ross, D. T., Ciaravino, G., Sørlie, T., Troyanskaya, O., Diehn, M., Wang, Y. C., Duran, G. E., Sikic, T. L., Caldeira, S., et al. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-05-0279 · Cited by 327
Identification by cDNA microarray of genes involved in ovarian carcinogenesis.
Ono, K., Tanaka, T., Tsunoda, T., Kitahara, O., Kihara, C., Okamoto, A., Ochiai, K., Takagi, T., & Nakamura, Y. (2000) · PubMed · Cited by 307
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Jazaeri, A. A., Yee, C. J., Sotiriou, C., Brantley, K. R., Boyd, J., & Liu, E. T. (2002) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282
Reles, A., Wen, W., Schmider, A., Gee, C., Runnebaum, I. B., Kilian, U., Jones, L. A., El‐Naggar, A. K., Minguillon, C., Schönborn, I., et al. (2001) · PubMed · Cited by 282
Berchuck, A., Iversen, E. S., Lancaster, J. M., Pittman, J., Luo, J., Lee, P., Murphy, S., Dressman, H. K., Febbo, P. G., West, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2398 · Cited by 266
Self-citationGene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer
Spentzos, D., Levine, D. A., Ramoni, M. F., Joseph, M., Gu, X., Boyd, J., Libermann, T. A., & Cannistra, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.070 · Cited by 255
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., & Woodward, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1589 · Cited by 213
Genetic analysis of early- versus late-stage ovarian tumors.
Shridhar, V., Lee, J., Pandita, A., Iturria, S., Avula, R., Staub, J., Morrissey, M., Calhoun, E., Sen, A., Kalli, K., et al. (2001) · PubMed · Cited by 196
Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V. R., Chuang, Y. E., Khan, J., Sotiriou, C., Aprelikova, O., Yee, C. J., Zorn, K. K., Birrer, M. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2682 · Cited by 192
The p53 tumor suppressor gene frequently is altered in gynecologic cancers
Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., & Bast, R. C. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70414-7 · Cited by 184
Self-citationSpectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian Cancer
Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R. C., & Berchuck, A. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.18.1513 · Cited by 184
Self-citationMolecular profiling of platinum resistant ovarian cancer
Helleman, J., Jansen, M. P. H. M., Span, P. N., van Staveren, I. L., Massuger, L. F. A. G., Meijer‐van Gelder, M. E., Sweep, F. C. G. J., Ewing, P. C., van der Burg, M. E. L., Stoter, G., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21599 · Cited by 165
Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer
Spentzos, D., Levine, D. A., Kolia, S., Otu, H. H., Boyd, J. A., Libermann, T. A., & Cannistra, S. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9363 · Cited by 136
Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers
Lancaster, J. M., Dressman, H. K., Whitaker, R. S., Havrilesky, L. J., Gray, J., Marks, J. R., Nevins, J. R., & Berchuck, A. (2003) · Journal of the Society for Gynecologic Investigation · doi:10.1016/j.jsgi.2003.07.004 · Cited by 108
Self-citationSawiris, G. P., Sherman‐Baust, C. A., Becker, K. G., Cheadle, C., Teichberg, D., & Morin, P. J. (2002) · PubMed · Cited by 104
Sparse Statistical Modelling in Gene Expression Genomics
Lucas, J. E., Carvalho, C. M., Wang, Q., Bild, A., Nevins, J. R., & West, M. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511584589.009 · Cited by 103
Self-citationBerchuck, A., Iversen, E. S., Lancaster, J. M., Dressman, H. K., West, M., Nevins, J. R., & Marks, J. R. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.02.005 · Cited by 101
Self-citationWong, K., Cheng, R. S., & Mok, S. C. (2001) · BioTechniques · doi:10.2144/01303dd05 · Cited by 88
Schmider, A., Gee, C., Friedmann, W. G., Lukas, J. J., Press, M. F., Lichtenegger, W., & Reles, A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5748 · Cited by 59
Molecular aspects of ovarian cancer.
Wenham, R., Lancaster, J., & Berchuck, A. (2002) · Best Practice & Research: Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2002.0298 · Cited by 53
Self-citationHavrilesky, L. J., Secord, A. A., Whitaker, R. S., Marks, J. R., & Berchuck, A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6464 · Cited by 44
Self-citationThe Gynecologic Oncology Group experience in ovarian cancer
McGuire, W. P., Brady, M. F., & Ozols, R. F. (1999) · Annals of Oncology · doi:10.1016/s0923-7534(20)31481-2 · Cited by 28
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Von Hoff, D. D., Stephenson, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5983 · Cited by 647
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Self-citationBeyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Metadata
- Authors
- Dressman, H. K., Berchuck, A., Chan, G., Zhai, J., Bild, A., Sayer, R., Cragun, J., Clarke, J., Whitaker, R. S., Li, L., Gray, J., Marks, J., Ginsburg, G. S., Potti, A., West, M., Nevins, J. R., & Lancaster, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-10
- Volume
- 25
- Issue
- 5
- Pages
- 517-525
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113629984
- Cited by
- 282
- References
- 30
- FWCI
- 37.97
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.